MORSE Consulting
MORSE Consulting Inc. is a Canadian pharmaceutical market access strategy consultancy dedicated to providing honest, practical guidance to navigate the complexities of the Canadian healthcare system. They partner with clients throughout the entire product lifecycle, from early evidence development to reimbursement and post-market processes, aiming to bridge gaps in perspectives among key stakeholders to ensure positive outcomes for patients and the healthcare system. Their services include comprehensive market access launch strategies, landscape analysis, HTA planning, stakeholder engagement, portfolio and lifecycle strategies, and expert-led training. MORSE values excellence, integrity, respect, and collaboration, and is committed to delivering high-quality, tailored solutions to support long-term success.
Industries
Nr. of Employees
small (1-50)
MORSE Consulting
Toronto, Ontario, Canada, North America
Products
Reimbursement timelines and forecasting subscription (CRaFT)
Subscription dataset and report providing public market-access volume and timeline analyses across HTA, negotiation, and provincial listing steps, with periodic updates and therapeutic-area stratification.
Therapeutic-area sub-reports (oncology, rare disease)
Focused analytical sub-reports addressing reimbursement timelines, trends, and considerations specific to oncology and rare-disease therapies.
Reimbursement timelines and forecasting subscription (CRaFT)
Subscription dataset and report providing public market-access volume and timeline analyses across HTA, negotiation, and provincial listing steps, with periodic updates and therapeutic-area stratification.
Therapeutic-area sub-reports (oncology, rare disease)
Focused analytical sub-reports addressing reimbursement timelines, trends, and considerations specific to oncology and rare-disease therapies.
Services
Advisory engagements to develop tailored launch strategies across the product lifecycle, covering payer assessment, evidence alignment, risk mitigation, and negotiation planning.
Analytical services mapping market dynamics, stakeholder positions, and payer decision drivers to inform strategic choices and forecasting.
Strategic planning of evidence packages to support HTA submissions and (re)submissions, identifying evidence gaps and recommending study or RWE approaches.
Support for negotiation preparation and stakeholder engagement with public and private payers, including negotiation posture validation, stakeholder mapping, and meeting support.
Advisory for portfolio prioritization and life-cycle management to optimize commercial positioning and manage reimbursement threats.
Customizable training sessions and workshops covering Canadian HTA, public and private payer processes, RWE interpretation, and internal expectation-setting for reimbursement planning.
Advisory engagements to develop tailored launch strategies across the product lifecycle, covering payer assessment, evidence alignment, risk mitigation, and negotiation planning.
Analytical services mapping market dynamics, stakeholder positions, and payer decision drivers to inform strategic choices and forecasting.
Strategic planning of evidence packages to support HTA submissions and (re)submissions, identifying evidence gaps and recommending study or RWE approaches.
Support for negotiation preparation and stakeholder engagement with public and private payers, including negotiation posture validation, stakeholder mapping, and meeting support.
Advisory for portfolio prioritization and life-cycle management to optimize commercial positioning and manage reimbursement threats.
Customizable training sessions and workshops covering Canadian HTA, public and private payer processes, RWE interpretation, and internal expectation-setting for reimbursement planning.
Expertise Areas
- Canadian HTA and reimbursement processes (CADTH, pCODR, INESSS)
- Public-payer negotiation and pan-Canadian payer (pCPA) processes
- Pharmacoeconomics and budget-impact analysis
- Real-world evidence strategy and interpretation
Key Technologies
- Public-payer dataset analytics
- Reimbursement timeline forecasting models
- Pharmacoeconomic modelling
- Real-world evidence generation and analysis
News & Updates
A forum sponsored by MORSE Consulting Inc. on March 2, 2025, focusing on mastering market access.
An executive summary report on the use of outcomes-based agreements in Canada, available from MORSE.
A report on the use of outcomes-based agreements for drugs for rare diseases, available from MORSE.
A presentation on strategies to accelerate access to new therapies, presented by MORSE.
The 2024 Canadian Reimbursement & Forecasting Timelines (CRaFT) Mid-Year Update is now available.
An overview of the Canadian drug agency and its impact on market access, with insights from MORSE.
A forum sponsored by MORSE Consulting Inc. on March 2, 2025, focusing on mastering market access.
An executive summary report on the use of outcomes-based agreements in Canada, available from MORSE.
A report on the use of outcomes-based agreements for drugs for rare diseases, available from MORSE.
A presentation on strategies to accelerate access to new therapies, presented by MORSE.
The 2024 Canadian Reimbursement & Forecasting Timelines (CRaFT) Mid-Year Update is now available.
An overview of the Canadian drug agency and its impact on market access, with insights from MORSE.